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http://dx.doi.org/10.1016/j.pedneo.2Background: Various studies have investigated the efficacies of mometasone furoate monohy-
drate (MFM) and fluticasone propionate (FP) nasal sprays for adults. However, research on their
effectiveness for children is limited. This study compares the efficacies of MFM and FP nasal
sprays in pediatric patients with perennial-allergic rhinitis.
Materials and methods: For this study, 94 perennial allergic rhinitis patients aged 6e12 years
were randomly assigned to two treatment groups: an MFM group and an FP group. Treatment
was provided for 4 weeks. The effects of the two agents were compared using the Pediatric
Rhinoconjunctivitis Quality of Life Questionnaire and total symptom scores (TSSs).
Nasal-peak expiratory flow rates and eosinophil percentage in nasal smears were also com-
pared between the two groups.
Results: Patients in the MFM group exhibited significant improvement in their TSS (tZ 2.65,
p < 0.05). A detailed TSS analysis showed MFM to be more effective for relieving nasal symp-
toms, whereas FP was more effective for relieving non-nasal symptoms. Patient questionnaire
scores suggested a significant reduction in symptoms for both the MFM (t Z 7.23, p < 0.01)
and FP (tZ 5.43, p < 0.01) groups. The flow rate test results indicated significant improve-
ments in the MFM group (t Z 2.27, p < 0.05).
Conclusion: Following the 4-week therapy, MFM provided greater improvement compared to
FP for symptoms of childhood perennial-allergic rhinitis. Based on their TSSs, the MFM groupllergy, Asthma and Rheumatology, Department of Pediatrics, Chung Shan Medical University Hospital,
Road, Taichung 402, Taiwan.
w (K.-H. Lue).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
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240 K.-K. Mak et alexperienced more effective relief of nasal symptoms, whereas the FP group experienced more
effective relief of non-nasal symptoms.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Allergic rhinitis (AR) is a common chronic condition among
children that is typically diagnosed by age 6 years. In
western countries, an estimated 10e25% of the population
has AR, with 30e60 million people affected annually in the
USA.1 Rhinitis is characterized by recurrent chronic nasal
symptoms such as congestion, rhinorrhea (often including
postnasal drip), nasal itching, sneezing, and conjunctiva
irritation. AR causes sleep disturbance, impairs psychoso-
cial functioning, and reduces life quality.2
AR treatment presents a significant medical challenge.
The Allergic Rhinitis and its Impact on Asthma (ARIA)
guidelines recommend intranasal corticosteroids as the
first-line treatment for patients with moderate to severe or
persistent rhinitis.3 For adults, several intranasal cortico-
steroid treatment options exist. However, for children (age
>4 years) the treatment options are limited. Mometasone
furoate monohydrate (MFM; Nasonex) and fluticasone pro-
pionate (FP; Flixonase) nasal sprays have been approved by
the Food and Drug Administration (FDA) in Taiwan for
treating childhood AR. A multicenter study with patients
aged 12e77 years found that both MFM and FP adequately
controlled symptoms of perennial rhinitis and were well
tolerated.4 However, clinical physicians lack information on
the effects of MFM compared to FP intranasal steroids for
children with perennial AR. This study was a clinical trial
comparing the efficacies of MFM and FP nasal sprays for
treating perennial AR in children aged 6e12 years.
2. Materials and Methods
2.1. Participants
This study was conducted in the Division of Allergy, Asthma,
and Rheumatology of the Department of Pediatrics at
Chung Shan Medical University Hospital, Taichung, Taiwan,
between December 2010 and June 2011. The study was
approved by the Chung Shan Medical University Hospital
Institutional Review Board, and written parental consent
was obtained prior to commencement. The study did not
receive the MFM and FP Corporate Support Grant. The in-
clusion criteria were: (1) moderate-to-severe perennial AR
(defined in the ARIA classification as AR that occurs
throughout the year) for at least 1 year; (2) a positive re-
action to mite-specific IgE (Pharmacia, Uppsala, Sweden;
entering this study >0.35 kUA/L); and (3) allergy to house
dust mites confirmed by a skin-prick test response.
Test-allergen extracts were prepared from dust mites
(Alyostal; Stallergenes, Paris, France). All patients were
required to undergo a control test (negative control with
normal saline). In positive skin-prick test responses, theskin becomes red and swollen with a wheal >3 mm in
diameter.
The exclusion criteria were: (1) a positive response to
other allergens; (2) deformities of the ear, nose, or throat, or
infection in the 2 weeks preceding the initial visit; (3) med-
ication consumption that may affect allergy symptoms (such
as oral antihistamines, decongestants, steroids, or leuko-
triene antagonists)within 2weeks prior to the study or during
the study period; (4) upper and lower respiratory-tract
infection within 2 weeks prior to the study; (5) intranasal
corticosteroid use within 2 weeks prior to the study; and (6)
nasal polyp disease. In total, 94 children with perennial AR
aged 6e12 years met the inclusion criteria for this study.
2.2. Study design
In the initial-screening visit, comprehensive medical and
allergy histories were obtained for all participants.
Daily-activity diaries were provided to the participants, with
instructions to record all symptoms once treatment began.
Participant medication history was reviewed to ensure that
they had not used an H1 antagonist, decongestant, oral ste-
roid, or intranasal corticosteroid in the preceding 2 weeks.
During the baseline visit, nasal-peak expiratory flow rate
(nPEFR) tests and examinations of the eosinophil percentage
in nasal smears were performed; patients were also
instructed to complete the Pediatric Rhinoconjunctivitis
Quality of Life Questionnaire (PRQLQ). The diaries of patient
activity for the preceding 7 days were also reviewed.
The study design was randomized, prospective, and con-
trolled. The participants were randomly divided into two
groups. Of the 94 participants, 47 received a 100 mg dose of
MFM nasal spray (1 spray/nostril) daily, and the remaining 47
participants received a 100 mg dose of FP nasal spray (1
spray/nostril) daily. Numerous envelopes were placed into
a box, and the enrolled patients were instructed to randomly
select one envelope. Patients were treated for 4 weeks and
then transferred to our outpatient clinic. Physical examina-
tions, nasal smears for eosinophil percent, and nPEFR tests
were performed, and all daily diary cards were collected.
Patients were then instructed to complete the PRQLQ again.
2.3. Total symptom score
Rhinitis symptoms were measured using a 4-point scale, with
scores as follows: 0 denoted “none” (no noticeable symp-
toms); 1 denoted “mild” (symptoms are noticeable but not
bothersome); 2 denoted “moderate” (symptoms are notice-
able and occasionally bothersome); and 3 denoted “severe”
(symptoms are generally bothersome and occasionally
extremely bothersome). The patients recorded their daily
scores for four nasal symptoms (rhinorrhea, nasal stuffiness,













Figure 1 Mean value of nasal peak expiratory flow rate in
baseline and Week 4. By paired t test, a Z 0.05, *p < 0.05.
Baseline means the first day of treatment. Y axis is the average
mean value of nasal peak expiratory flow rate. X axis is the
therapy period. Mometasone furoate monohydrate group
(t Z 2.27, p < 0.05) significantly increased the nasal peak
expiratory flow rate value.
Nasonex and Flixonase sprays for rhinitis 241(throat itching, eye itching, tearing, and eye congestion).
The symptom scores for younger childrenwere recordedwith
parental assistance. Patients’ total symptom score (TSS) was
the sum of the eight recorded symptom scores. Baseline TSS
and each symptom score were calculated as the mean of the
daily scores during the baseline period of 7 days.5
2.4. PRQLQ
The PRQLQ contained 23 questions in five categories (nasal
symptoms, eye symptoms, practical problems, activity
limitations, and other symptoms).6 The children recalled
their experiences from previous weeks and responded to
each question using a 7-point scale (ranging from 0 to 6).7
The questionnaire was completed within 5 minutes, and
the scores for younger children (age < 9 years) were
recorded with parental assistance.
2.5. nPEFR
The nPEFR was measured using a Mini-Wright peak expir-
atory flow meter (HS clement Clarke international com-
pany). The flow meter was equipped with a purpose-built
facemask that incorporated an effective facial seal, which
was worn by the patients during tests. Each patient was
instructed to blow forcefully through the nose after taking
a deep breath, while keeping the mouth firmly closed. ForTable 1 Demography of characteristics and baseline data
of the both mometasone furoate monohydrate (MFM) and
fluticasone propionate (FP) groups.
Variables MFM group FP group
No. 40 43
Gender
Male 23 (57.5%) 24 (55.8%)
Female 17 (42.5%) 19 (44.2%)
Height (cm) 125.92  14.05 123.35  13.43
Weight (kg) 28.79  12.11 26.81  10.01
Atopy history 32 (80.0%) 34 (79.1%)
Age (y) 9.96  2.18 9.14  2.41
Allergic rhinitis history
Own 40 (100%) 43 (100%)
Mother 12 (30.0%) 19 (44.2%)
Father 19 (47.5%) 22 (51.2%)
Siblings 17 (42.5%) 16 (37.2%)
Asthma history
Own 0 (0.0%) 3 (7.0%)
Mother 2 (5.0%) 1 (2.3%)
Father 0 (0.0%) 1 (2.3%)
Siblings 2 (5.0%) 1 (2.3%)
Atopic dermatitis history
Own 0 (0.0%) 2 (4.7%)
Mother 0 (0.0%) 0 (0.0%)
Father 2 (5.0%) 0 (0.0%)
Siblings 4 (10.0%) 1 (2.3%)
Serum IgE (IU/mL) 482.80  314.34 537.49  519.83
Eosinophil % in
nasal smear
54.68  16.10 59.08  16.38
Data are presented as n (%) or mean  standard deviation.younger children, the nPEFR test was conducted with
parental assistance. The test was performed three times,
and the highest result was recorded.
2.6. Eosinophil percentage in nasal-smear
examinations
The underside of the patients’ inferior turbinate was swab-
bed with a cotton wool bud, and the obtained sample was
smeared onto a glass slide. These slides were then stained
with Leu stain and examined using a light microscope. An
experienced cytologist, blind to the participants’ clinical
status, performed this assay. The patients’ eosinophil per-
centage in nasal smears was determined by counting a mini-
mum of 100 leukocytes, and the eosinophil count was
expressed as a proportion of the total number of leukocytes.8
2.7. Statistical analysis
Statistical analysis was performed using SPSS/PC12.0 soft-
ware (SPSS, Inc., Chicago, IL, USA). All data are expressed












Figure 2 Mean value of Pediatric Rhinoconjunctivitis Quality
of Life Questionnaire (PRQLQ) in baseline and Week 4. By
paired t test, aZ 0.05, *p < 0.01. Baseline means the first day
of treatment. Y axis is the average mean value of PRQLQ. X axis
is the therapy period. Both mometasone furoate monohydrate
group (t Z 7.23, p < 0.01) and fluticasone propionate group














Figure 3 Mean value of total symptom score (TSS) in baseline
and Week 4. By paired t test, a Z 0.05, *p < 0.05. Baseline
means the first week of treatment. Y axis is the average mean
value of the TSS. X axis is the therapy period. Mometasone
furoate monohydrate group (tZ 2.65, p < 0.05) significantly
reduced the TSS value.
242 K.-K. Mak et alt test was used to compare the improvement rates of the
mean nasal PEFR, the mean PRQLQ score (for each ques-
tion), and the mean TSS for the two groups. A p value <0.05
was considered statistically significant.
3. Results
A total of 94 patients were enrolled in this study, with 47
patients assigned to an MFM group and 47 patients assignedTable 2 Change from baseline (first day of treatment) of indiv
Life Questionnaire in the mometasone furoate monohydrate grou
Variables Baseline Wee
Nose symptoms domains
Sneezing 2.67  1.40 1.21
Runny nose 2.88  1.54 1.08
Stuffy 3.79  1.84 1.00
Itchy nose 3.08  1.41 1.29
Eye symptoms domains
Itchy eyes 2.29  1.55 1.42
Watery eyes 1.08  1.06 0.54
Swollen 0.67  0.70 0.38
Sore eyes 0.79  0.93 0.33
Practical problems domains
Rub nose and eyes 2.92  1.44 1.54
Blow nose 2.96  1.78 1.04
Carry Kleenex 2.75  1.78 0.83
Take medications 2.67  1.81 1.04
Feel embarrassed 2.29  1.65 0.83
Other symptoms domains
Thirst 1.29  1.23 0.75
Don’t feel well all over 2.00  1.44 1.17
Irritable 2.29  1.73 1.04
Tired 1.92  1.59 1.33
Headache 1.67  1.76 0.67
Itchy throat 1.46  1.61 0.54
Activities limitation domains
Playing outdoors 1.33  1.86 0.46
Hard to get to sleep at night 3.00  1.82 1.58
Hard to pay attention 2.79  1.67 1.46
Wake up during the night 2.50  1.72 1.21
By paired t test, a Z 0.05, *p < 0.05, **p < 0.01, ***p < 0.001. Datato an FP group. However, 11 patients (7 from the MFM group
and 4 from the FP group) with incomplete TSS recordings
during the treatment period were subsequently excluded
from this study. The mean age of the patients was 9 years
(range, 6e12 years). No significant differences were
observed between the two groups for baseline demographics
or health characteristics (Table 1).
Regarding nPEFR, the MFM group improved significantly
after 4 weeks of treatment (from 67.71  23.24 at the
baseline to 72.88  28.20 at Week 4; p < 0.05) (Figure 1).
For PRQLQ scores, both the MFM group (2.22  0.92 to
0.99  0.69; p < 0.01) and the FP group (2.08  0.99 to
1.17  0.80; p < 0.01) improved significantly during treat-
ment (Figure 2). The MFM group showed a greater decline in
PRQLQ scores compared to that of the FP group; however,
the difference was non-significant (tZ 1.23, pZ 0.224).
The TSS for the MFM group also improved significantly fol-
lowing treatment (from 2.80  2.55 to 1.49  1.30;
p < 0.05; Figure 3).
The scores for each item in the PRQLQ were then ana-
lyzed. The MFM group exhibited a significant improvement
for all symptom categories excluding eye symptoms, with
swollen eyes (t Z 1.50, p Z 0.148) and sore eyes
(t Z 1.80, p Z 0.086), showing limited or nonsignificant
improvement. In other symptom categories, no significant
improvement was noted for thirst (t Z 2.01, p Z 0.056)idual symptom items Pediatric Rhinoconjunctivitis Quality of
p (n Z 40).
k 4 Difference t p
 1.10 1.46  1.50 4.75 0.000***
 1.02 1.79  1.64 5.35 0.000***
 1.06 2.79  1.91 7.16 0.000***
 0.86 1.79  1.44 6.08 0.000***
 1.25 0.88  1.48 2.89 0.008**
 0.83 0.54  1.18 2.25 0.034*
 0.71 0.29  0.95 1.50 0.148
 0.76 0.46  1.25 1.80 0.086
 1.28 1.38  1.64 4.12 0.000***
 1.08 1.92  1.86 5.04 0.000***
 0.82 1.92  1.91 4.92 0.000***
 1.00 1.63  2.02 3.95 0.001***
 1.09 1.46  1.25 5.71 0.000***
 0.94 0.54  1.32 2.01 0.056
 0.92 0.83  1.37 2.97 0.007**
 1.08 1.25  1.22 5.00 0.000***
 1.13 0.58  1.61 1.77 0.090
 0.92 1.00  1.59 3.09 0.005**
 0.78 0.92  1.32 3.41 0.002**
 0.78 0.88  1.73 2.48 0.021*
 1.61 1.42  1.53 4.54 0.000***
 1.59 1.33  1.40 4.65 0.000***
 1.47 1.29  1.57 4.02 0.001**
are presented as means  standard deviation.
Nasonex and Flixonase sprays for rhinitis 243and tiredness (tZ 1.77, pZ 0.09; Table 2). The FP group
also showed improvement in all categories excluding eye
symptoms, with limited or nonsignificant improvement for
watery eyes (t Z 1.99, p Z 0.054) and sore eyes
(t Z 1.07, p Z 0.291; Table 3).
For both the MFM and FP groups, we analyzed the
change in TSS from baseline (Week 1) to Weeks 2, 3, and 4
of the treatment. The TSS was the sum of the eight
symptom scores. No statistically significant differences
were observed between the two groups for baseline (W1)
TSS scores. The MFM group experienced improvement in AR
nasal symptoms, with symptom improvements of rhinor-
rhea, nasal stuffiness, nasal itching, and sneezing achiev-
ing statistical significance. The FP group experienced
improved non-nasal AR symptoms, with improved eye-
itching symptoms, achieving statistical significance
(Table 4).
An examination of eosinophil percentage in nasal smears
showed statistically significant improvements for both the
MFM (from 54.68  16.10 at baseline to 39.30  15.09 at
Week 4; p < 0.01) and FP (from 59.08  16.38 at baseline to
40.92  14.84 at Week 4; p < 0.01) groups following
treatment. No significant differences were observed be-
tween the two groups (t Z 1.13, p Z 0.26).Table 3 Change from baseline of individual symptom items Ped
fluticasone propionate group (n Z 43).
Variables Baseline Wee
Nose symptoms domains
Sneezing 2.40  1.43 1.56
Runny nose 2.49  1.44 1.53
Stuffy 3.65  1.72 1.74
Itchy nose 2.91  1.80 1.47
Eye symptoms domains
Itchy eyes 2.21  1.66 1.21
Watery eyes 0.91  1.06 0.56
Swollen 1.12  1.47 0.63
Sore eyes 0.74  1.09 0.58
Practical problems domains
Rub nose and eyes 2.91  1.77 1.88
Blow nose 2.74  1.72 1.35
Carry Kleenex 2.28  1.83 1.12
Take medications 2.65  2.25 1.00
Feel embarrassed 2.19  1.48 1.23
Other symptoms domains
Thirst 1.05  1.25 0.60
Don’t feel well all over 2.21  1.41 1.44
Irritable 2.09  1.41 1.33
Tired 2.23  1.46 1.37
Headache 1.16  1.66 0.65
Itchy throat 1.07  1.44 0.56
Activities limitation domains
Playing outdoors 1.56  1.79 0.72
Hard to get to sleep at night 2.49  1.62 1.33
Hard to pay attention 2.86  1.51 1.81
Wake up during the night 1.93  1.49 1.14
By paired t test, a Z 0.05, *p < 0.05, **p < 0.01, ***p < 0.001. Data4. Discussion
Previous clinical trials have found that intranasal cortico-
steroid sprays are effective for relieving adult AR.9e11
However, clinical trials assessing the efficacy of such
sprays for children with AR are scant.12e14 Related liter-
ature does not report research comparing the use of MFM to
FP in children. Our study results show that both intranasal
corticosteroid sprays (MFM and FP) were effective for
managing AR in children. MFM treatment was associated
with a significant improvement in mean nPEFR values, mean
PRQLQ scores, mean TSS, and eosinophil percentage in
nasal smears. A further detailed analysis of TSS indicated
that MFM was more effective than FP for relieving nasal
symptoms, whereas FP was more effective than MFM for
relieving non-nasal symptoms.
We also found that the nPEFR test results improved
significantly for children with AR treated with MFM, but
not for children treated with FP. Sharma and Baroody
showed that MFM nasal sprays significantly reduced nasal-
peak inspiratory flow in AR.15,16 Their results were con-
sistent with those of this study. By contrast, FP nasal
sprays did not significantly reduce the expression of
endothelial vascular cell adhesion molecule-1 or theiatric Rhinoconjunctivitis Quality of Life Questionnaire in the
k 4 Difference t p
 1.05 0.84  1.46 3.75 0.001**
 1.20 0.95  1.70 3.67 0.001**
 1.18 1.91  1.84 6.81 0.000***
 1.12 1.44  1.71 5.53 0.000***
 1.10 1.00  1.60 4.09 0.000***
 0.80 0.35  1.15 1.99 0.054
 0.69 0.49  1.32 2.43 0.019*
 0.76 0.16  1.00 1.07 0.291
 1.31 1.02  1.82 3.69 0.001**
 1.25 1.40  2.05 4.47 0.000***
 1.40 1.16  1.94 3.93 0.000***
 1.30 1.65  2.45 4.42 0.000***
 1.29 0.95  1.62 3.87 0.000***
 0.88 0.44  1.16 2.50 0.017*
 1.40 0.77  1.82 2.76 0.009**
 1.27 0.77  1.56 3.23 0.002**
 1.16 0.86  1.63 3.47 0.001**
 1.00 0.51  1.61 2.09 0.043*
 0.93 0.51  1.55 2.17 0.036*
 1.10 0.84  1.96 2.80 0.008**
 1.25 1.16  1.76 4.34 0.000***
 1.58 1.05  1.72 4.00 0.000***
 1.32 0.79  1.83 2.83 0.007**
are presented as means  standard deviation.
Table 4 Changes in total symptom score from baseline (Week 1) of individual symptoms.
Mometasone furoate
monohydrate group (n Z 40)
p Fluticasone propionate




W1eW2 0.42  3.27 0.539 0.12  2.73 0.782
W1eW3 1.54  4.58 0.113 0.84  3.86 0.163
W1eW4 2.17  4.74 0.035* 0.58  4.33 0.384
Nasal stuffiness
W1eW2 1.13  3.61 0.140 0.87  3.21 0.082
W1eW3 1.83  4.58 0.062 0.35  4.16 0.585
W1eW4 2.04  4.31 0.029* 0.91  4.36 0.180
Nasal itching
W1eW2 0.85  2.76 0.143 0.84  2.76 0.053
W1eW3 1.52  3.28 0.033* 0.91  3.25 0.075
W1eW4 1.54  3.28 0.031* 1.42  3.27 0.007**
Sneezing
W1eW2 0.48  2.53 0.364 0.51  2.25 0.144
W1eW3 1.73  2.80 0.006** 0.38  2.88 0.387
W1eW4 1.73  2.98 0.009** 0.69  3.23 0.170
Non-nasal symptoms
Throat itching
W1eW2 0.19  1.88 0.630 0.02  2.06 0.941
W1eW3 0.50  1.84 0.195 0.36  2.65 0.377
W1eW4 0.44  2.97 0.478 0.08  2.57 0.837
Eye itching
W1eW2 0.27  1.47 0.375 1.14  2.36 0.003**
W1eW3 0.83  2.66 0.139 1.58  3.28 0.003**
W1eW4 0.63  3.39 0.375 1.37  3.53 0.014*
Tearing
W1eW2 0.38  0.95 0.065 0.34  1.55 0.160
W1eW3 0.71  1.69 0.052 0.36  1.96 0.234
W1eW4 0.44  2.05 0.307 0.50  1.75 0.068
Eye congestion
W1eW2 0.17  0.72 0.267 0.20  1.20 0.285
W1eW3 0.63  1.61 0.070 0.15  1.71 0.565
W1eW4 0.17  1.61 0.618 0.19  1.89 0.521
By paired t test, aZ 0.05, *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as means  standard deviation. W1 means the period
from day 1 to day 7 of the first week. Scoring for each 1 week period was calculated as (daytime score þ nighttime score)/2.
244 K.-K. Mak et alnumber of tumor necrosis factor-a or interleukin-1b
mRNAþ cells.17 This finding is reflected in clinical out-
comes in which nasal sprays are ineffective for altering
nasal or lower airway variables.17
In this study, both the MFM and FP groups showed
limited improvement in PRQLQ scores for eye symptoms
associated with childhood AR. Bielory et al18 and Rodrigo
et al19 reported that the use of an FP nasal spray once
daily effectively relieves ocular and nasal symptoms in
adolescents and adults with AR. The patients included in
the present study were all children. FP delivered through
the intranasal route has an absolute bioavailability aver-
age of <2%, and MFM shows extremely low bioavailability
(<1%) in plasma.20,21 Thus, nasal sprays may fail to con-
trol ocular symptoms if they cannot induce any mean-
ingful movement of allergens, their mediators, or
antiallergy drugs from the nasal cavity to the ocular
surface.22We found MFM sprays to be significantly more effective
than FP sprays for relieving nasal symptoms, as evidenced by
the differences in TSS between the two groups. However, FP
was significantly more effective than MFM for relieving
non-nasal symptoms, which was also evidenced by the TSS
differences. Keith and Scadding23 indicated that not all
intranasal corticosteroids are consistent for managing the
ocular symptoms of seasonal AR. Meltzer et al24 also repor-
ted that patients rated several sensory attributes of MFM
nasal sprays as significantly superior to those of FP nasal
sprays. One study found that FP nasal sprays were ineffec-
tive regarding mucociliary transport time.25 Another repor-
ted that MFM nasal sprays (200 mg twice daily) rapidly
improved nasal polyposis symptoms and swelling.26 These
results may be due to patients objectively perceiving MFM
nasal sprays to be superior in because in clinical settings.
This study was subject to several limitations. First, most
of the younger participants required parental assistance to
Nasonex and Flixonase sprays for rhinitis 245record their responses to the PRQLQ and TSS, and may thus
reflect the experiences of parents rather than their children.
Recall bias also contributed to the inconsistent TSS and
PRQLQ results. However, we employed various examina-
tions, including nPEFR and the eosinophil percentage in
nasal smears, to reduce questionnaire bias. Second, we did
not classify the severity of patients’ AR in this study; oth-
erwise, the possible response differences to treatment for
mild-persistent, severe-intermittent, or severe-persistent
types of AR could have been analyzed. Finally, we lacked
patient data on family-member smoking habits and house-
hold pets, which are factors that may affect AR symptoms.27
The results of our 4-week treatment program showed
that MFM nasal sprays were more effective than FP nasal
sprays for improving the symptoms of childhood perennial
AR. Although the TSS for the FP group did not show signif-
icant improvement, the patients experienced more effec-
tive relief from non-nasal symptoms.References
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